ASCHOPLEX: A generalizable approach for the automatic segmentation of choroid plexus.

Choroid plexus Deep neural networks Ensemble Magnetic resonance imaging Semantic segmentation

Journal

Computers in biology and medicine
ISSN: 1879-0534
Titre abrégé: Comput Biol Med
Pays: United States
ID NLM: 1250250

Informations de publication

Date de publication:
25 Sep 2024
Historique:
received: 09 04 2024
revised: 23 08 2024
accepted: 16 09 2024
medline: 27 9 2024
pubmed: 27 9 2024
entrez: 26 9 2024
Statut: aheadofprint

Résumé

The Choroid Plexus (ChP) plays a vital role in brain homeostasis, serving as part of the Blood-Cerebrospinal Fluid Barrier, contributing to brain clearance pathways and being the main source of cerebrospinal fluid. Since the involvement of ChP in neurological and psychiatric disorders is not entirely established and currently under investigation, accurate and reproducible segmentation of this brain structure on large cohorts remains challenging. This paper presents ASCHOPLEX, a deep-learning tool for the automated segmentation of human ChP from structural MRI data that integrates existing software architectures like 3D UNet, UNETR, and DynUNet to deliver accurate ChP volume estimates. Here we trained ASCHOPLEX on 128 T1-w MRI images comprising both controls and patients with Multiple Sclerosis. ASCHOPLEX's performances were evaluated using traditional segmentation metrics; manual segmentation by experts served as ground truth. To overcome the generalizability problem that affects data-driven approaches, an additional fine-tuning procedure (ASCHOPLEX ASCHOPLEX showed superior performance compared to commonly used methods like FreeSurfer and Gaussian Mixture Model both in terms of Dice Coefficient (ASCHOPLEX 0.80, ASCHOPLEX These results highlight the high accuracy, reliability, and reproducibility of ASCHOPLEX ChP segmentations.

Sections du résumé

BACKGROUND BACKGROUND
The Choroid Plexus (ChP) plays a vital role in brain homeostasis, serving as part of the Blood-Cerebrospinal Fluid Barrier, contributing to brain clearance pathways and being the main source of cerebrospinal fluid. Since the involvement of ChP in neurological and psychiatric disorders is not entirely established and currently under investigation, accurate and reproducible segmentation of this brain structure on large cohorts remains challenging. This paper presents ASCHOPLEX, a deep-learning tool for the automated segmentation of human ChP from structural MRI data that integrates existing software architectures like 3D UNet, UNETR, and DynUNet to deliver accurate ChP volume estimates.
METHODS METHODS
Here we trained ASCHOPLEX on 128 T1-w MRI images comprising both controls and patients with Multiple Sclerosis. ASCHOPLEX's performances were evaluated using traditional segmentation metrics; manual segmentation by experts served as ground truth. To overcome the generalizability problem that affects data-driven approaches, an additional fine-tuning procedure (ASCHOPLEX
RESULTS RESULTS
ASCHOPLEX showed superior performance compared to commonly used methods like FreeSurfer and Gaussian Mixture Model both in terms of Dice Coefficient (ASCHOPLEX 0.80, ASCHOPLEX
CONCLUSION CONCLUSIONS
These results highlight the high accuracy, reliability, and reproducibility of ASCHOPLEX ChP segmentations.

Identifiants

pubmed: 39326265
pii: S0010-4825(24)01249-6
doi: 10.1016/j.compbiomed.2024.109164
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

109164

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Valentina Visani (V)

Department of Information Engineering, University of Padova, Padova, Italy. Electronic address: valentina.visani@phd.unipd.it.

Mattia Veronese (M)

Department of Information Engineering, University of Padova, Padova, Italy; Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. Electronic address: mattia.veronese@unipd.it.

Francesca B Pizzini (FB)

Department of Engineering for Innovation Medicine, University of Verona, Verona, Italy. Electronic address: francescabenedetta.pizzini@univr.it.

Annalisa Colombi (A)

Unit of Neurology, Fondazione Poliambulanza, Brescia, Italy. Electronic address: annalisa.colombi@poliambulanza.it.

Valerio Natale (V)

Department of Diagnostic and Public Health, University of Verona, Verona, Italy. Electronic address: valerio.natale01@gmail.com.

Corina Marjin (C)

Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy. Electronic address: corinamarjin@gmail.com.

Agnese Tamanti (A)

Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy. Electronic address: agnese.tamanti@univr.it.

Julia J Schubert (JJ)

Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. Electronic address: julia.schubert@kcl.ac.uk.

Noha Althubaity (N)

Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK; Department of Radiological Sciences, College of Applied Medical Science, King Saud bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi Arabia. Electronic address: thubaityn@ksau-hs.edu.sa.

Inés Bedmar-Gómez (I)

Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. Electronic address: ines.bg.med@gmail.com.

Neil A Harrison (NA)

Cardiff University Brain Research Imaging Centre (CUBRIC), Cardiff University, Cardiff, UK. Electronic address: HarrisonN4@cardiff.ac.uk.

Edward T Bullmore (ET)

Department of Psychiatry, School of Clinical Medicine, University of Cambridge, Cambridge, UK; Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK; Immuno-Psychiatry, Immuno-Inflammation Therapeutic Area Unit, GlaxoSmithKline R&D, Stevenage, UK. Electronic address: etb23@medschl.cam.ac.uk.

Federico E Turkheimer (FE)

Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. Electronic address: federico.turkheimer@kcl.ac.uk.

Massimiliano Calabrese (M)

Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy. Electronic address: massimiliano.calabrese@univr.it.

Marco Castellaro (M)

Department of Information Engineering, University of Padova, Padova, Italy. Electronic address: marco.castellaro@unipd.it.

Classifications MeSH